Know Cancer

or
forgot password

Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer


Inclusion Criteria:



- Signed informed consent.

- At least 18 years of age.

- On tamoxifen for at least 3 months for adjuvant therapy.

- On a stable diet for past 1 week before blood sampling.

- Compliant with tamoxifen medication.

- Completed adjuvant chemotherapy and/or adjuvant radiation therapy.

Exclusion Criteria:

• Patients should not be on the list of medications for the last 1 week before accrual to
the study

Type of Study:

Observational

Study Design:

Observational Model: Case-Crossover, Time Perspective: Cross-Sectional

Outcome Measure:

To determine the steady state pharmacokinetics of tamoxifen and its metabolites

Safety Issue:

No

Principal Investigator

Chiung Ing Wong, MRCP, MB ChB

Investigator Role:

Principal Investigator

Investigator Affiliation:

National University Hospital, Singapore

Authority:

Singapore: Domain Specific Review Boards

Study ID:

BR02/06/06

NCT ID:

NCT00717015

Start Date:

November 2005

Completion Date:

Related Keywords:

  • Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Breast Neoplasms

Name

Location